MMP-13 enzyme and pH responsive theranostic nanoplatform for osteoarthritis.

J Nanobiotechnology

Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China.

Published: August 2020

Stimulus-responsive therapy permits precise control of therapeutic effect only at lesion of interest, which determines it a promising method for diagnosis and imaging-guided precision therapy. The acid environment and overexpressed matrix metalloproteinases-13 (MMP-13) are typical markers in osteoarthritis (OA), which enables the development of stimulus-responsive drug delivery system with high specificity for OA. We herein demonstrate a nano-micelle based stimuli-responsive theranostic strategy with reporting and drug release controlled by acidic pH and MMP-13 for OA therapy. Such nanoplatform is incorporated with a motif specifically targeting on cartilage, a motif responsive to matrix metalloproteinases-13 to specifically report OA condition and biodynamics of nano-micelles, an anti-inflammatory drug (e.g., psoralidin (PSO)) from traditional Chinese medicine, and a biocompatible polymeric skeleton for sustainable drug release in response to the acidic OA condition. The high effectiveness of this targeted precision therapy is demonstrated comprehensively by both in vitro and vivo evidences.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450974PMC
http://dx.doi.org/10.1186/s12951-020-00666-7DOI Listing

Publication Analysis

Top Keywords

precision therapy
8
matrix metalloproteinases-13
8
drug release
8
mmp-13 enzyme
4
enzyme responsive
4
responsive theranostic
4
theranostic nanoplatform
4
nanoplatform osteoarthritis
4
osteoarthritis stimulus-responsive
4
therapy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!